Hormonal
Thiazolidinediones (TZDs) increase the risk of hospitalization for heart failure through fluid retention mediated by sodium reabsorption.
If you have Type 2 Diabetes and Heart Failure, especially if it is moderate to severe (NYHA class III or IV), you should likely avoid Thiazolidinediones (like Actos or Avandia). These drugs cause fluid retention and significantly increase the risk of being hospitalized for heart failure. Your doctor will likely choose a different medication.
Thiazolidinediones increase the risk of hospitalized HF through increasing renal tubular sodium reabsorption mediated via both the genomic and non-genomic action of PPARγ... Rosiglitazone markedly increased the risk of HHF (HR, 7.04 (95% CI, 1.60–31.0))
Why this rating
Supported by multiple RCTs (DREAM, PROactive) and meta-analyses showing increased HF risk.
Source
Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism
Chih‐Neng Hsu et al. · Life · 2023
DOI 10.3390/life13041024
More from this paper
- SGLT2 inhibitors significantly reduce the risk of hospitalization for heart failure and cardiovascular death in patients with type 2 diabetes, regardless of baseline glycemic control or heart failure status.Strong
- DPP-4 inhibitors (specifically Saxagliptin and Alogliptin) may increase the risk of hospitalization for heart failure, whereas Sitagliptin and Linagliptin appear neutral.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →